These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1320 related items for PubMed ID: 10079679

  • 1. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J.
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [Abstract] [Full Text] [Related]

  • 2. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ.
    Hematol J; 2004 Feb; 5(2):93-102. PubMed ID: 15048058
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ.
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [Abstract] [Full Text] [Related]

  • 4. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ, Thiele J.
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [Abstract] [Full Text] [Related]

  • 5. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Aug; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond.
    Michiels JJ.
    Hematology; 2005 Jun; 10 Suppl 1():215-23. PubMed ID: 16188676
    [Abstract] [Full Text] [Related]

  • 11. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [Abstract] [Full Text] [Related]

  • 12. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [Abstract] [Full Text] [Related]

  • 13. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
    Tefferi A.
    Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
    [Abstract] [Full Text] [Related]

  • 14. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ, De Raeve H, Hebeda K, Lam KH, Berneman Z, Schroyens W, Schwarz J.
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J.
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [Abstract] [Full Text] [Related]

  • 19. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J, Kvasnicka HM, Zankovich R, Diehl V.
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [Abstract] [Full Text] [Related]

  • 20. Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders - aids to diagnosis and classification.
    Thiele J, Kvasnicka HM, Fischer R.
    Ann Hematol; 1999 Nov; 78(11):495-506. PubMed ID: 10602893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.